An-Art Study: Atrioventricular (AV) Node Ablation in Cardiac Resynchronisation Therapy
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Nov 29, 2005
Trial Information
Current as of May 13, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients who had a CRT pacemaker or CRT-ICD implanted and who are under optimal medical therapy, can be included 3 months after implantation of the device.
- Exclusion Criteria:
- • The sole exclusion criterion is no consent of the patient.
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Christian Sticherling, M.D.
Principal Investigator
University Hospital Basel, Cardiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials